BIOMAT Database Logo BIOMAT Database Logo

Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets. 1998

A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
Dpt. of Medicina Clinica, University La Sapienza, Rome, Italy.

In the present study we analyzed some circulating lymphocyte subsets in eleven patients affected by Graves' disease before and after three and six months of methimazole treatment. Peripheral blood mononuclear cells were studied by a panel of monoclonal antibodies with single and double fluorescence cytometric analysis. Our results demonstrated an increased percentage of CD5+B cells and HLADR+T lymphocytes at the beginning of the disease in comparison to the normal controls (p < 0.001), and a significant decrease after six months of treatment (p < 0.01 and p < 0.05, respectively). The CD4+ CD45RA+ subset was significantly reduced in untreated Graves' patients in comparison to the normal group (p < 0.01), and increased towards normalization after six months of treatment. The significant modifications of lymphocyte subsets, as well as the reduction of thyroid autoantibodies, support a direct or mediated effect of methimazole on the immune system.

UI MeSH Term Description Entries
D008297 Male Males
D008713 Methimazole A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme. Methymazol,Thiamazole,1-Methyl-2-mercaptoimidazole,Favistan,Mercasolyl,Mercazol,Mercazole,Mercazolyl,Merkazolil,Methizol,Methylmercaptoimidazole,Metisol,Metizol,Strumazol,Tapazole,Thiamazol Henning,Thiamazol Hexal,Thimazol,Thyrozol,Tiamazol,Tirodril,1 Methyl 2 mercaptoimidazole,Henning, Thiamazol,Hexal, Thiamazol
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006111 Graves Disease A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy). Basedow's Disease,Exophthalmic Goiter,Goiter, Exophthalmic,Graves' Disease,Basedow Disease,Hyperthyroidism, Autoimmune,Basedows Disease,Disease, Basedow,Disease, Basedow's,Disease, Graves,Disease, Graves',Exophthalmic Goiters,Goiters, Exophthalmic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent
D013956 Antithyroid Agents Agents that are used to treat hyperthyroidism by reducing the excessive production of thyroid hormones. Antithyroid Agent,Antithyroid Drug,Goitrogen,Goitrogens,Thyroid Antagonists,Antithyroid Drugs,Antithyroid Effect,Antithyroid Effects,Agent, Antithyroid,Agents, Antithyroid,Antagonists, Thyroid,Drug, Antithyroid,Drugs, Antithyroid,Effect, Antithyroid,Effects, Antithyroid
D016176 T-Lymphocyte Subsets A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells. T-Cell Subset,T-Cell Subsets,T-Lymphocyte Subset,Subset, T-Cell,Subset, T-Lymphocyte,Subsets, T-Cell,Subsets, T-Lymphocyte,T Cell Subset,T Cell Subsets,T Lymphocyte Subset,T Lymphocyte Subsets
D018956 CD5 Antigens Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156) Antigens, CD5,CD5 Antigen,Leu-1 Antigen,T1 Antigen,Antigen, CD5,Leu 1 Antigen

Related Publications

A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.
November 1988, Clinical and experimental immunology,
A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
CD5+ B lymphocytes and T-cell subsets in a case of juvenile rheumatoid arthritis.
May 1992, Annals of the New York Academy of Sciences,
A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
Serial analysis of the effects of methimazole therapy on circulating B cell subsets in Graves' disease.
November 1996, The Journal of endocrinology,
A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
[CD5 positive b-lymphocytes in autoimmunity: possible role in Graves' disease].
January 1995, Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques,
A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
Circulating T cell subsets in euthyroid Graves' disease.
April 1983, Journal of endocrinological investigation,
A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
Evidence for differential responsiveness of human CD5+ and CD5- B cell subsets to T cell-independent mitogens.
February 1991, European journal of immunology,
A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
CD5 positive immunoregulatory B cell subsets.
August 1988, American journal of hematology,
A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
Th17 and Treg cells in adolescents with Graves' disease. Impact of treatment with methimazole on these cell subsets.
May 2014, Autoimmunity,
A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
Treatment of Graves' disease with methimazole in children alters the proliferation of Treg cells and CD3+ T lymphocytes.
January 2014, Folia histochemica et cytobiologica,
A Paggi, and A Amoroso, and G M Ferri, and A Mariotti, and C Pellegrino, and A Afeltra
CD5+ B lymphocytes and other lymphocyte subsets in primary Sjögren's syndrome.
April 1992, The Netherlands journal of medicine,
Copied contents to your clipboard!